Eli Lilly and Company (NYSE:LLY) had its price objective raised by BMO Capital Markets from $71.00 to $73.00 in a report published on Tuesday. BMO Capital Markets currently has an underperform rating on the stock.

LLY has been the subject of several other research reports. Piper Jaffray Companies reissued a buy rating and issued a $103.00 price objective on shares of Eli Lilly and in a research note on Thursday, August 31st. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $94.00 price target for the company in a research report on Monday, July 17th. Jefferies Group LLC restated a buy rating and issued a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Credit Suisse Group cut shares of Eli Lilly and from an outperform rating to a neutral rating and upped their price target for the company from $84.23 to $88.00 in a research report on Tuesday. Finally, Cowen and Company restated a buy rating and issued a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $88.57.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.86 EPS.

ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Price Target Raised to $73.00” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/13/eli-lilly-and-company-lly-price-target-raised-to-73-00.html.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 990,000 shares of company stock worth $82,949,650 over the last ninety days. Insiders own 0.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in LLY. BlackRock Inc. grew its position in shares of Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Janus Henderson Group PLC grew its position in shares of Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after buying an additional 9,223,251 shares during the period. Dodge & Cox grew its position in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after buying an additional 5,964,955 shares during the period. Renaissance Technologies LLC grew its position in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after buying an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. 75.72% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.